Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Radiance Biopharma, Inc. a biotechnology company developing next generation Antibody Drug Conjugates (“ADCs”) and Bispecific ADCs (“BsADCs), announced that it has been selected to participate in Seed ...

JPMorgan Chase & Co. (NYSE: JPM) ("JPMorganChase" or the "Firm") has declared dividends on the outstanding shares of the Firm ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

AdventHealth and Novant Health have set $30 billion annual revenue targets, fueled by a growing demand for care and interest ...

Alignment Healthcare is looking a bit lonely at the J.P. Morgan Healthcare Conference. CEO John Kao doesn’t really mind.

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

The fixed-income trading business posted $2.74 billion in revenue, driven by gains in currencies, mortgages and credit ...

JPMorgan Chase & Co. has released its fourth-quarter and full-year 2024 financial results. Results can be found at the Firm’s ...

As set forth above, the company’s financial results for the quarter and full year ended December 31, 2024 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter ...